Calico Life Sciences, a longevity-focused biotech affiliated with Alphabet, has entered into a licensing agreement valued at up to $596 million with Chinese company Mabwell Bioscience. The deal grants Calico exclusive global rights to Mabwell's investigational monoclonal antibody 9MW3811, targeting interleukin-11 (IL-11) pathways implicated in age-related diseases. Phase 1 clinical trials for 9MW3811 are underway in China and Australia, and an Investigational New Drug application is active with the FDA. Calico’s collaboration aims to advance anti-aging therapeutics by modulating IL-11 signaling, excluding commercialization rights within greater China.